about
Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic miceHIP14, a novel ankyrin domain-containing protein, links huntingtin to intracellular trafficking and endocytosisThe Sirtuin 2 microtubule deacetylase is an abundant neuronal protein that accumulates in the aging CNSEvaluation of histone deacetylases as drug targets in Huntington's disease models. Study of HDACs in brain tissues from R6/2 and CAG140 knock-in HD mouse models and human patients and in a neuronal HD cell modelThe PTB domain of ShcA couples receptor activation to the cytoskeletal regulator IQGAP1Cellular localization and development of neuronal intranuclear inclusions in striatal and cortical neurons in R6/2 transgenic miceClinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.Candidate glutamatergic and dopaminergic pathway gene variants do not influence Huntington's disease motor onsetTAA repeat variation in the GRIK2 gene does not influence age at onset in Huntington's disease.Population stratification may bias analysis of PGC-1α as a modifier of age at Huntington disease motor onset.Common SNP-based haplotype analysis of the 4p16.3 Huntington disease gene region.Genome-wide significance for a modifier of age at neurological onset in Huntington's disease at 6q23-24: the HD MAPS study.A genome scan for modifiers of age at onset in Huntington disease: The HD MAPS study.Huntington's disease: prospects for neuroprotective therapy 10 years after the discovery of the causative genetic mutation.Mechanisms of copper ion mediated Huntington's disease progressionSp1 and TAFII130 transcriptional activity disrupted in early Huntington's disease.Complexity and heterogeneity: what drives the ever-changing brain in Huntington's disease?Optimization of an HTRF Assay for the Detection of Soluble Mutant Huntingtin in Human Buffy Coats: A Potential Biomarker in Blood for Huntington DiseaseA novel method for detecting 7-methyl guanine reveals aberrant methylation levels in Huntington diseaseReduced creatine kinase as a central and peripheral biomarker in Huntington's diseaseThe mTOR kinase inhibitor Everolimus decreases S6 kinase phosphorylation but fails to reduce mutant huntingtin levels in brain and is not neuroprotective in the R6/2 mouse model of Huntington's disease.Resistance of alpha -synuclein null mice to the parkinsonian neurotoxin MPTP.Cysteine oxidation within N-terminal mutant huntingtin promotes oligomerization and delays clearance of soluble protein.A cell-based assay for aggregation inhibitors as therapeutics of polyglutamine-repeat disease and validation in Drosophila.Iron accumulates in Huntington's disease neurons: protection by deferoxamineA tale of two factors: what determines the rate of progression in Huntington's disease? A longitudinal MRI study.Transcriptional modulator H2A histone family, member Y (H2AFY) marks Huntington disease activity in man and mouseA systems-level "misunderstanding": the plasma metabolome in Huntington's diseaseUsing advances in neuroimaging to detect, understand, and monitor disease progression in Huntington's disease.Translating therapies for Huntington's disease from genetic animal models to clinical trials.A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse.The therapeutic role of creatine in Huntington's disease.The sirtuin 2 inhibitor AK-7 is neuroprotective in Huntington's disease mouse models.Identification of phenylbutyrate-generated metabolites in Huntington disease patients using parallel liquid chromatography/electrochemical array/mass spectrometry and off-line tandem mass spectrometry.Drug targeting of dysregulated transcription in Huntington's diseaseRho Kinase Pathway Alterations in the Brain and Leukocytes in Huntington's Disease.Alterations in brain transition metals in Huntington disease: an evolving and intricate story.Linking SNPs to CAG repeat length in Huntington's disease patients.Altered white matter microstructure in the corpus callosum in Huntington's disease: implications for cortical "disconnection".Venezuelan kindreds reveal that genetic and environmental factors modulate Huntington's disease age of onset
P50
Q28171073-56358CE4-75B5-4B58-8635-20A4A02C37DEQ28209859-BE52B985-C5D6-4EF9-9FDC-0EA539F0E26FQ28244138-DC219C60-6920-489D-B478-1CF1B0E6C216Q28475537-9CB0E077-DB02-4615-9AAE-B4F162DAA326Q28505266-70262CAA-0569-4729-8809-C6F254D31A27Q28510296-64B99E06-B8E0-4068-AE02-D2F7D8CF3F97Q30278084-3BFD6F63-C92A-4FC3-80C2-87C05F04B76FQ30416270-DA629FE0-0320-4CD7-8080-AA8E451A792CQ30417570-972AA9A1-846A-420B-B607-735B16C43BA8Q30424048-45F4F2FA-53A6-4062-AAAA-8FABAC603AEDQ30425027-763CBAD4-B7FF-48C0-A661-14BE1BDD6638Q30445842-A0AE14CA-4F3D-4940-AA2D-7653180145EAQ30448206-9C30DD66-1796-4514-AEE4-F0A4A9A84661Q31149947-283BDA8D-42C0-4354-B234-ABD09AB1DF51Q33280572-CD28340B-34AE-48FB-B82C-DAC59E650E57Q33292417-71E2C8DF-EDE8-47BE-AA40-05588BCB54A2Q33619310-AA0304C1-3357-4C0D-B891-8CA7722D35C2Q33807006-2ACF1A99-576A-4A09-A755-99B8775BB56EQ33874603-67398622-7DC6-4DF4-9FA6-BE51D77C801EQ33945688-45855C27-F40B-4A58-BB1C-E547660E809BQ34011801-83C26E0A-EE55-4216-A891-C94A668D6C11Q34394747-00F34E36-84F1-4C65-A468-89DB3718916CQ34979158-632B6E34-A4F6-45A9-A7B9-7BF09684E26DQ35022497-89D541AA-DC6A-45D7-AFDB-4C721A4EC826Q35023030-D7944338-3A6C-4774-9FDA-12C33777EBC9Q35162891-C2238494-83B6-4D45-9A5C-90FD75136908Q35345762-8E21998D-15CE-46E5-A9C3-2092BE3ADBD7Q35935105-404E5C85-857B-49AA-A0D1-87AE26A9DFF7Q36045301-F141592D-3813-4542-B010-F317BCE1B98FQ36045315-41FC5F50-51AA-4E22-A663-AB91C24C3E03Q36082278-86A0E006-5EA7-400D-9D90-57D5E4D6E013Q36213329-A8B9236E-55FC-4570-AF30-C27688F6F648Q36501584-64C72B65-D21E-4230-AEA1-DDD3B9D8D788Q36598779-34856861-24D0-41F6-8C86-240B5C86C1DFQ36767264-EF44545D-5DD8-47F0-97EA-1FB198CAFBEAQ36772887-55D6E8B3-81A9-4027-AB1A-61F14EB2498CQ36838442-AE53B57F-B43F-4B9F-AF94-2CBC65E5E3BCQ36982924-9348C4DD-7701-476B-BB20-A0B54BC958CAQ37052324-2763AE95-40B8-41E2-AAD8-1EBA3B456DE6Q37073913-A427F309-AF7A-48E8-93C5-BC77ED1BFA6C
P50
name
Steven M Hersch
@en
type
label
Steven M Hersch
@en
prefLabel
Steven M Hersch
@en